CN102257009A - 具有针对dc-sign的结合特异性的配体 - Google Patents

具有针对dc-sign的结合特异性的配体 Download PDF

Info

Publication number
CN102257009A
CN102257009A CN2009801529594A CN200980152959A CN102257009A CN 102257009 A CN102257009 A CN 102257009A CN 2009801529594 A CN2009801529594 A CN 2009801529594A CN 200980152959 A CN200980152959 A CN 200980152959A CN 102257009 A CN102257009 A CN 102257009A
Authority
CN
China
Prior art keywords
lip1
seq
sign
variable domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801529594A
Other languages
English (en)
Chinese (zh)
Inventor
R·M·德维尔德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domantis Ltd
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of CN102257009A publication Critical patent/CN102257009A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN2009801529594A 2008-10-21 2009-10-19 具有针对dc-sign的结合特异性的配体 Pending CN102257009A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
US61/107085 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
CN102257009A true CN102257009A (zh) 2011-11-23

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801529594A Pending CN102257009A (zh) 2008-10-21 2009-10-19 具有针对dc-sign的结合特异性的配体

Country Status (16)

Country Link
US (1) US20110257373A1 (https=)
EP (1) EP2356149A2 (https=)
JP (1) JP2012506237A (https=)
KR (1) KR20110071139A (https=)
CN (1) CN102257009A (https=)
AR (1) AR073905A1 (https=)
AU (1) AU2009306424A1 (https=)
BR (1) BRPI0919714A2 (https=)
CA (1) CA2740856A1 (https=)
EA (1) EA201100488A1 (https=)
IL (1) IL212086A0 (https=)
MX (1) MX2011004244A (https=)
TW (1) TW201019962A (https=)
UY (1) UY32189A (https=)
WO (1) WO2010046337A2 (https=)
ZA (1) ZA201102763B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125271A1 (zh) * 2022-12-13 2024-06-20 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046338A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Composition for targeting dendritic cells
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2601115A1 (en) * 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
AU2007300543A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SI J,ET AL.: "ACCESSION NO:AY73916.1,anti-Toxoplasma gondii SAG1 immunoglobulin S3 light chain variable region partial", 《GENBANK DATABASE》 *
杨帆，杨秀荣: "表面等离子体共振技术在分子生物学中的应用", 《生物工程学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024125271A1 (zh) * 2022-12-13 2024-06-20 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Also Published As

Publication number Publication date
AU2009306424A1 (en) 2010-04-29
WO2010046337A2 (en) 2010-04-29
BRPI0919714A2 (pt) 2015-12-08
AR073905A1 (es) 2010-12-09
TW201019962A (en) 2010-06-01
KR20110071139A (ko) 2011-06-28
WO2010046337A3 (en) 2010-07-01
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CA2740856A1 (en) 2010-04-29
JP2012506237A (ja) 2012-03-15
UY32189A (es) 2010-05-31
EP2356149A2 (en) 2011-08-17
ZA201102763B (en) 2012-09-26
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25

Similar Documents

Publication Publication Date Title
US12428497B2 (en) Multispecific antibody constructs
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
CN110831626B (zh) 单价抗备解素抗体及抗体片段
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2010505436A (ja) コンディショナルな方法で所望の分子に結合するアミノ酸配列
CN105121467A (zh) 抗cd47抗体及其使用方法
EP1888641A1 (en) Serum albumin binding proteins
KR20070084069A (ko) Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
EA035517B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TWI906795B (zh) 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用
CN102257009A (zh) 具有针对dc-sign的结合特异性的配体
WO2023142297A1 (zh) Muc1结合分子及其应用
CN114685666B (zh) 抗间皮素纳米抗体及其应用
WO2023051618A1 (zh) Ctla-4结合分子及其应用
CN106062193A (zh) 新型与人tlr2及人tlr4结合的双特异性抗体
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
WO2024094076A1 (zh) 一种gipr结合蛋白及其应用
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
WO2023011650A1 (zh) 一种多特异性抗体及其用途
RU2784673C2 (ru) Конструкции полиспецифических антител
JP2025528101A (ja) 多重特異性ポリペプチド複合体
CN120769865A (zh) 结合分子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111123